pazopanib + paclitaxel

Pazopanib + paclitaxel is a combination regimen of two antineoplastic agents used in the treatment of various solid tumors, including advanced renal cell carcinoma and soft tissue sarcoma. Pazopanib is an oral small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 1 (VEGFR1), vascular endothelial growth factor receptor 2 (VEGFR2), vascular endothelial growth factor receptor 3 (VEGFR3), platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), c-Kit, FGFR, IL-2 receptor, LcK and c-Fms. By inhibiting these kinases involved in angiogenesis and tumor proliferation pathways such as RAS/RAF/MEK/ERK and PI3K/AKT/mTOR, pazopanib blocks tumor blood vessel formation and growth[3][5][6]. Paclitaxel is a microtubule-stabilizing agent that binds to the β subunit of tubulin to prevent microtubule disassembly during mitosis. This disrupts cell division and induces apoptosis in cancer cells[8]. The combination has shown synergistic antitumor effects due to complementary mechanisms—pazopanib’s antiangiogenic activity enhances the cytotoxic effect of paclitaxel on rapidly dividing tumor cells[1][4]. Pazopanib can also increase plasma concentrations of paclitaxel by weakly inhibiting CYP3A4/CYP2C8-mediated metabolism[1][6].

Brand names

TaxolAbraxaneVotrient

Other names

None